Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.06. | Cantor Fitzgerald behält Kursziel von 13 US-Dollar für Taysha Gene Therapies bei | 1 | Investing.com Deutsch | ||
13.06. | Taysha Gene Therapies price target maintained at $13 by Cantor Fitzgerald | 2 | Investing.com | ||
12.06. | Taysha gene therapies stock rating reiterated by Cantor Fitzgerald | 1 | Investing.com | ||
06.06. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 222 | GlobeNewswire (Europe) | DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
04.06. | Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates | 3 | Insider Monkey | ||
03.06. | Taysha reports progress in Rett syndrome gene therapy trials | 1 | Investing.com | ||
03.06. | Taysha berichtet über Fortschritte bei Gentherapiestudien für Rett-Syndrom | 6 | Investing.com Deutsch | ||
TAYSHA GENE THERAPIES Aktie jetzt für 0€ handeln | |||||
03.06. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program | 4 | GlobeNewswire (USA) | ||
03.06. | Canaccord Genuity raises Taysha Gene Therapies stock price target | 4 | Investing.com | ||
02.06. | Where Taysha Gene Therapies Stands With Analysts | 1 | Benzinga.com | ||
29.05. | Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? | 1 | Benzinga.com | ||
29.05. | Cantor Fitzgerald maintains $7 target on Taysha Gene shares | 1 | Investing.com | ||
29.05. | Taysha-Aktie steigt nach positiver Studienplanung und FDA-Abstimmung | 2 | Investing.com Deutsch | ||
29.05. | Taysha stock surges on positive trial design and FDA alignment | 2 | Investing.com | ||
29.05. | JMP raises Taysha stock target to $6 on positive FDA alignment | 2 | Investing.com | ||
29.05. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
28.05. | Taysha Gene Therapies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.05. | Taysha Gene Therapies commences underwritten public offering | 4 | Seeking Alpha | ||
28.05. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent ... | 247 | GlobeNewswire (Europe) | Natural history data analysis established patients = six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains... ► Artikel lesen | |
28.05. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,461 | -0,67 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,834 | -1,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million | -Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones-
-BioCryst plans to use proceeds to... ► Artikel lesen | |
KUROS BIOSCIENCES | 30,060 | -0,40 % | Kuros Biosciences AG: Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Market Day in Zürich | Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Markets Day in Zürich
Schlieren (Zürich), Switzerland, May 13, 2025 - Kuros Biosciences ("Kuros"... ► Artikel lesen | |
TEMPUS AI | 56,44 | -0,67 % | Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? |